
Chris Viehbacher, Biogen CEO (Scott Eells/Bloomberg via Getty Images)
Following Alzheimer’s drug approval, analysts dish on what they expect from Biogen in 2023
Biogen has been on a roller coaster over the past couple of years. It survived the controversial approval and disastrous rollout of its first Alzheimer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.